The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Deep learning for drug response prediction in cancer
Abstract
Predicting the sensitivity of tumors to specific anti-cancer treatments is a challenge of paramount importance for precision medicine. Machine learning(ML) algorithms can be trained on high-throughput screening data to develop models that are able to predict the response of cancer cell lines and patients to novel drugs or drug combinations. Deep learning (DL) refers to a distinct class of ML algorithms that have achieved top-level performance in a variety of fields, including drug discovery. These types of models have unique characteristics that may make them more suitable for the complex task of modeling drug response based on both biological and chemical data, but the application of DL to drug response prediction has been unexplored until very recently. The few studies that have been published have shown promising results, and the use of DL for drug response prediction is beginning to attract greater interest from researchers in the field. In this article, we critically review recently published studies that have employed DL methods to predict drug response in cancer cell lines. We also provide a brief description of DL and the main types of architectures that have been used in these studies. Additionally, we present a selection of publicly available drug screening data resources that can be used to develop drug response prediction models. Finally, we also address the limitations of these approaches and provide a discussion on possible paths for further improvement. Contact: mrocha@di.uminho.pt
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
LeCun, Y., Bengio, Y., & Hinton, G. (2015) · Nature · doi:10.1038/nature14539 · Cited by 84,126
ImageNet: A large-scale hierarchical image database
Deng, J., Dong, W., Socher, R., Li, L.-J., Li, K., & Fei-Fei, L. (2009) · 2009 IEEE Conference on Computer Vision and Pattern Recognition · doi:10.1109/cvpr.2009.5206848 · Cited by 65,333
The Elements of Statistical Learning
Hastie, T., Tibshirani, R., & Friedman, J. (2009) · Springer Series in Statistics · doi:10.1007/978-0-387-84858-7 · Cited by 25,970
A Unified Approach to Interpreting Model Predictions
Lundberg, S., & Lee, S.-I. (2017) · arXiv · doi:10.48550/arxiv.1705.07874 · Cited by 23,707
Reducing the dimensionality of data with neural networks
Hinton, G. E., & Salakhutdinov, R. R. (2006) · Science · doi:10.1126/science.1127647 · Cited by 20,928
A fast learning algorithm for deep belief nets
Hinton, G. E., Osindero, S., & Teh, Y.-W. (2006) · Neural Computation · doi:10.1162/neco.2006.18.7.1527 · Cited by 16,336
Rudin, C. (2019) · Nature Machine Intelligence · doi:10.1038/s42256-019-0048-x · Cited by 10,561
TensorFlow: Large-Scale Machine Learning on Heterogeneous Distributed Systems
Abadi, M., Agarwal, A., Barham, P., Brevdo, E., Chen, Z., Citro, C., Corrado, G. S., Davis, A., Dean, J., Devin, M., et al. (2016) · arXiv · doi:10.48550/arxiv.1603.04467 · Cited by 9,408
Learning Deep Architectures for AI
Bengio, Y. (2009) · Foundations and Trends® in Machine Learning · doi:10.1561/2200000006 · Cited by 9,239
DrugBank 5.0: a major update to the DrugBank database for 2018
Wishart, D. S., Feunang, Y. D., Guo, A. C., Lo, E. J., Marcu, A., Grant, J. R., Sajed, T., Johnson, D., Li, C., Sayeeda, Z., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1037 · Cited by 8,404
Research works printed but not linked: 74
- Yang, 2013, Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells, Nucleic Acids Res, 41, D955, 10.1093/nar/gks1111 · DOI · Paper page
- Basu, 2013, An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules, Cell, 154, 1151, 10.1016/j.cell.2013.08.003 · DOI · Paper page
- Iorio, 2016, A landscape of pharmacogenomic interactions in cancer, Cell, 166, 740, 10.1016/j.cell.2016.06.017 · DOI · Paper page
- Menden, 2674, Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen, Nat Commun, 10, 2019
- Huang, 2017, Open source machine-learning algorithms for the prediction of optimal cancer drug therapies, PLoS One, 12, 1, 10.1371/journal.pone.0186906 · DOI
- Costello, 2014, A community effort to assess and improve drug sensitivity prediction algorithms, Nat Biotechnol, 32, 1202, 10.1038/nbt.2877 · DOI · Paper page
- Gönen, 2014, Drug susceptibility prediction against a panel of drugs using kernelized Bayesian multitask learning, Bioinformatics, 30, 556, 10.1093/bioinformatics/btu464 · DOI
- Cortés-Ciriano, 2015, Improved large-scale prediction of growth inhibition patterns using the NCI60 cancer cell line panel, Bioinformatics, 32, 85, 10.1093/bioinformatics/btv529 · DOI
- Gayvert, 2017, A computational approach for identifying synergistic drug combinations, PLoS Comput Biol, 13, 10.1371/journal.pcbi.1005308 · DOI
- Menden, 2013, Machine learning prediction of cancer cell sensitivity to drugs based on genomic and chemical properties, PLoS One, 8, 10.1371/journal.pone.0061318 · DOI · Paper page
- Kalamara, 2018, How to find the right drug for each patient? Advances and challenges in pharmacogenomics, Curr Opin Syst Biol, 10, 53, 10.1016/j.coisb.2018.07.001 · DOI
- Goh, 2017, Deep learning for computational chemistry, J Comput Chem, 38, 1291, 10.1002/jcc.24764 · DOI · Paper page
- Korotcov, 2017, Comparison of deep learning with multiple machine learning methods and metrics using diverse drug discovery data sets, Mol Pharm, 14, 4462, 10.1021/acs.molpharmaceut.7b00578 · DOI · Paper page
- Brunton, 2011, Goodman and Gilman’s The Pharmacological Basis of Therapeutics
- Srivastava, 2014, Dropout: a simple way to prevent neural networks from overfitting, J Mach Learn Res, 15, 1929
- Tallarida, 2011, Quantitative methods for assessing drug synergism, Genes Cancer, 2, 1003, 10.1177/1947601912440575 · DOI · Paper page
- Mohri, 2012, Foundations of Machine Learning
- Lo, 2018, Machine learning in chemoinformatics and drug discovery, Drug Discov Today, 23, 1538, 10.1016/j.drudis.2018.05.010 · DOI · Paper page
- Duvenaud, 2015, Convolutional networks on graphs for learning molecular fingerprints, J Chem Inf Model, 56, 399
- Goodfellow, 2016, Deep Learning
- Bengio, 2013, Representation learning: a review and new perspectives, IEEE Trans Pattern Anal Mach Intell, 35, 1798, 10.1109/TPAMI.2013.50 · DOI · Paper page
- Kingma, 2015, A method for stochastic optimization. In: 3rd International Conference on Learning Representations, ICLR 2015, San Diego, CA, USA, May 7-9, 2015, Conference Track Proceedings
- Salakhutdinov, 2009, Deep Boltzmann machines. In: Proceedings of the Twelfth International Conference on Artificial Intelligence and Statistics, AISTATS 2009, Clearwater Beach, Florida, USA, 448
- Preuer, 2018, DeepSynergy: predicting anti-cancer drug synergy with deep learning, Bioinformatics, 34, 1538, 10.1093/bioinformatics/btx806 · DOI · Paper page
- Ching, 2018, Opportunities and obstacles for deep learning in biology and medicine, J R Soc Interface, 15, 10.1098/rsif.2017.0387 · DOI · Paper page
- Cortés-Ciriano, 2019, KekuleScope: prediction of cancer cell line sensitivity and compound potency using convolutional neural networks trained on compound images, J Chem, 11, 41, 10.1186/s13321-019-0364-5 · DOI
- Lipton, 2015, A Critical review of recurrent neural networks for sequence, Learning
- Ding, 2018, Precision oncology beyond targeted therapy: combining omics data with machine learning matches the majority of cancer cells to effective therapeutics, Mol Cancer Res, 16, 269, 10.1158/1541-7786.MCR-17-0378 · DOI · Paper page
- Li, 2019, DeepDSC: a deep learning method to predict drug sensitivity of cancer cell lines, IEEE/ACM Trans Comput Biol Bioinform, 1
- Chiu, 2019, Predicting drug response of tumors from integrated genomic profiles by deep neural networks, BMC Med Genomics, 12, 10.1186/s12920-018-0460-9 · DOI · Paper page
- Chen, 2018, Predict effective drug combination by deep belief network and ontology fingerprints, J Biomed Inform, 85, 149, 10.1016/j.jbi.2018.07.024 · DOI
- Chollet, 2015, Keras
- Ramsundar, 2019, Deep Learning for the Life Sciences
- Shoemaker, 2006, The NCI60 human tumour cell line anticancer drug screen, Nat Rev, 6, 813, 10.1038/nrc1951 · DOI · Paper page
- Greshock, 2010, Molecular target class is predictive of in vitro response profile, Cancer Res, 70, 3677, 10.1158/0008-5472.CAN-09-3788 · DOI
- Li, 2019, The landscape of cancer cell line metabolism, Nat Med, 25, 850, 10.1038/s41591-019-0404-8 · DOI · Paper page
- Haverty, 2016, Reproducible pharmacogenomic profiling of cancer cell line panels, Nature, 533, 333, 10.1038/nature17987 · DOI · Paper page
- Mpindi, 2016, Consistency in drug response profiling, Nature, 540, E5, 10.1038/nature20171 · DOI
- Gholami, 2013, Global proteome analysis of the NCI-60 cell line panel, Cell Rep, 4, 609, 10.1016/j.celrep.2013.07.018 · DOI · Paper page
- Lamb, 2006, The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease, Science, 313, 1929, 10.1126/science.1132939 · DOI · Paper page
- Litichevskiy, 2018, A library of phosphoproteomic and chromatin signatures for characterizing cellular responses to drug perturbations, Cell Syst, 6, 424, 10.1016/j.cels.2018.03.012 · DOI
- Gillet, 2013, The clinical relevance of cancer cell lines, JNCI J Natl Cancer Inst, 105, 452, 10.1093/jnci/djt007 · DOI · Paper page
- Goodspeed, 2016, Tumor-derived cell lines as molecular models of cancer pharmacogenomics, Mol Cancer Res, 14, 3, 10.1158/1541-7786.MCR-15-0189 · DOI · Paper page
- Zhang, 2011, International cancer genome consortium data portal—a one-stop shop for cancer genomics data, Database, 2011, bar026, 10.1093/database/bar026 · DOI · Paper page
- Szklarczyk, 2016, STITCH 5: augmenting protein–chemical interaction networks with tissue and affinity data, Nucleic Acids Res, 44, D380, 10.1093/nar/gkv1277 · DOI · Paper page
- Harding, 2018, The IUPHAR/BPS guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY, Nucleic Acids Res, 46, D1091, 10.1093/nar/gkx1121 · DOI · Paper page
- Cowley, 2014, Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies, Sci Data, 1
- Tsherniak, 2017, Defining a cancer dependency map, Cell, 170, 564, 10.1016/j.cell.2017.06.010 · DOI · Paper page
- Whirl-Carrillo, 2012, Pharmacogenomics knowledge for personalized medicine, Clin Pharmacol Ther, 92, 414, 10.1038/clpt.2012.96 · DOI · Paper page
- Eduati, 2015, Prediction of human population responses to toxic compounds by a collaborative competition, Nat Biotechnol, 33, 933, 10.1038/nbt.3299 · DOI
- Mermel, 2011, GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers, Genome Biol, 12, 10.1186/gb-2011-12-4-r41 · DOI · Paper page
- Loewe, 1926, Effect of combinations: mathematical basis of problem, Arch Exp Pathol Pharmakol, 114, 313, 10.1007/BF01952257 · DOI · Paper page
- Rampášek, 2019, Dr.VAE: improving drug response prediction via modeling of drug perturbation effects, Bioinformatics, 35, 3743, 10.1093/bioinformatics/btz158 · DOI · Paper page
- Sharifi-Noghabi, 2019, MOLI: multi-omics late integration with deep neural networks for drug response prediction, Bioinformatics, 35, i501, 10.1093/bioinformatics/btz318 · DOI · Paper page
- Liu, 2019, Improving prediction of phenotypic drug response on cancer cell lines using deep convolutional network, BMC Bioinformatics, 20, 10.1186/s12859-019-2910-6 · DOI · Paper page
- Matlock, 2018, Investigation of model stacking for drug sensitivity prediction, BMC Bioinformatics, 19, 71, 10.1186/s12859-018-2060-2 · DOI
- Tan, 2018, Drug response prediction by ensemble learning and drug-induced gene expression signatures, Genomics, 111, 1078, 10.1016/j.ygeno.2018.07.002 · DOI
- Chang, 2018, Cancer drug response profile scan (CDRscan): a deep learning model that predicts drug effectiveness from cancer genomic signature, Sci Rep, 8
- Xia, 2018, Predicting tumor cell line response to drug pairs with deep learning, BMC Bioinformatics, 19, 10.1186/s12859-018-2509-3 · DOI
- Qin, 2012, Signaling network prediction by the ontology fingerprint enhanced Bayesian network, BMC Syst Biol, 6, S3, 10.1186/1752-0509-6-S3-S3 · DOI
- Pulley, 2020, Using what we already have: uncovering new drug repurposing strategies in existing omics data, Annu Rev Pharmacol Toxicol, 60, 10.1146/annurev-pharmtox-010919-023537 · DOI
- Aliper, 2016, Deep learning applications for predicting pharmacological properties of drugs and drug repurposing using transcriptomic data, Mol Pharm, 13, 2524, 10.1021/acs.molpharmaceut.6b00248 · DOI · Paper page
- Donner, 2018, Drug repurposing using deep embeddings of gene expression profiles, Mol Pharm, 15, 4314, 10.1021/acs.molpharmaceut.8b00284 · DOI
- Zeng, 2019, deepDR: a network-based deep learning approach to in silico drug repositioning, Bioinformatics, 10.1093/bioinformatics/btz418 · DOI · Paper page
- Xu, 2017, Seq2seq Fingerprint, 285
- Hop, 2018, Geometric deep learning autonomously learns chemical features that outperform those engineered by domain experts, Mol Pharm, 15, 4371, 10.1021/acs.molpharmaceut.7b01144 · DOI
- Li, 2016, A review on machine learning principles for multi-view biological data integration, Brief Bioinform, 19, 325
- Safikhani, 2016, Revisiting inconsistency in large pharmacogenomic studies, F1000Res, 5, 2333, 10.12688/f1000research.9611.1 · DOI
- Geeleher, 2016, Consistency in large pharmacogenomic studies, Nature, 540, E1, 10.1038/nature19838 · DOI
- Goodfellow, 2014, Generative adversarial nets, 2672
- Liu, 2019, Wasserstein GAN-based small-sample augmentation for new-generation artificial intelligence: a case study of cancer-staging data in biology, Engineering, 5, 156, 10.1016/j.eng.2018.11.018 · DOI · Paper page
- Shrikumar, 2017, Learning important features through propagating activation differences, 3145
- Sundararajan, Axiomatic attribution for deep networks, 3319
- Alvarez Melis, 2018, Towards robust interpretability with self-explaining neural networks, 7775
Cited by
Predicting drug response and synergy using a deep learning model of human cancer cells
Kuenzi, B. M., Park, J., Fong, S. H., Sanchez, K. S., Lee, J., Kreisberg, J. F., Ma, J., & Ideker, T. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.09.014 · Cited by 544
Deep learning in drug discovery: an integrative review and future challenges
Askr, H., Elgeldawi, E., Aboul Ella, H., Elshaier, Y. A. M. M., Gomaa, M. M., & Hassanien, A. E. (2023) · Artificial Intelligence Review · doi:10.1007/s10462-022-10306-1 · Cited by 390
Biology and medicine in the landscape of quantum advantages
Cordier, B. A., Sawaya, N. P. D., Guerreschi, G. G., & McWeeney, S. K. (2022) · Journal of The Royal Society Interface · doi:10.1098/rsif.2022.0541 · Cited by 87
“Examples that fit this criteria include the diagnosis and prognosis of rare phenotypes [433, 434], the identification of adverse multi-drug reactions from EHR data [435, 436], and the diagnosis of cancers [437] and their subtyping on the basis of clinical outcomes, such as drug sensitivity [438] and disease prognosis…”
BackgroundSuphavilai, C., Chia, S., Sharma, A., Tu, L., Da Silva, R. P., Mongia, A., DasGupta, R., & Nagarajan, N. (2021) · Genome Medicine · doi:10.1186/s13073-021-01000-y · Cited by 58
“Besides, a more fundamental challenge is the robustness of such models to diverse, unseen cell types [22].”
BackgroundBridging machine learning and peptide design for cancer treatment: a comprehensive review
Rezaee, K., & Eslami, H. (2025) · Artificial Intelligence Review · doi:10.1007/s10462-025-11148-3 · Cited by 34
Metadata
- Authors
- Baptista, D., Ferreira, P. G., & Rocha, M.
- Venue
- Briefings in Bioinformatics
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-01-17
- Volume
- 22
- Issue
- 1
- Pages
- 360-379
- ISSN
- 1467-5463 (ISSN-L)
- 1477-4054
- OpenAlex
- W3000469142
- Cited by
- 237
- References
- 49
- FWCI
- 11.30
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Funders
- Foundation for Science and Technology (UID/BIO/04469/2019, SFRH/BD/130913/2017)
- BioTecNorte operation (NORTE-01-0145-FEDER-000004)
- European Regional Development Fund
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Deep learning for drug response prediction in cancer. https://app.cochat.ai/papers/10.1093/bib/bbz171
- The paper
- Baptista, D., Ferreira, P. G., & Rocha, M. (2021). Deep learning for drug response prediction in cancer. Briefings in Bioinformatics. https://doi.org/10.1093/bib/bbz171
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.